Front Med (Lausanne). 2022 doi: 10.3389/fmed.2022.859330
Promising results for patients with diffuse cutaneous systemic sclerosis (dcSSc) skin fibrosis and digital ulcers (DU), using JAK1/2 inhibitor baricitinib.
Few available treatment options currently exist for the rare disabling connective tissue disease, systemic sclerosis. However, previous mouse model studies have shown that JAK2 inhibition can significantly improve skin fibrosis, reducing dermal thickening and collagen accumulation, in this high mortality disease.
As such, Hou, et al. assessed the efficacy of oral JAK1/2 inhibitor baricitinib in SSc patients, especially focusing on skin fibrosis and microvascular manifestations, with promising results.